Loading stock data…
HAE
$52.25-2.87 (-5.21%)
Market OpenUpdated 3:53 PM EDT
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Haemonetics Corporation in the Healthcare sector is trading at $52.25. The stock is currently near its 52-week low of $47.32, remaining 17.0% below its 200-day moving average. Technical signals show oversold RSI of 29 and bearish MACD signal, explaining why HAE maintains its current current market pressure. The Whystock Score of 70/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Oversold momentum (RSI 29) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$52.25
Potential Upside
28.2%
Whystock Fair Value$66.97
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus10 analysts
Buy
Mean target$81.10+55.2%
Range$62.00 – $108.00
Fundamentals
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting sof...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.86B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
16.84
Beta
Defensive asset. Lower volatility than the S&P 500.
0.36
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
17.92%
Volume
Today's trading volume
770,716
Recent News
HAE Stock Gains on Q4 Earnings & Revenue Beat, Gross Margin Cut
Haemonetics beats Q4 EPS and revenue estimates, shares rise 1.4%, but gross margin falls 120 basis points as the company sets its FY27 growth outlook.
Haemonetics Q4 Earnings Call Highlights
Haemonetics (NYSE:HAE) reported fiscal fourth-quarter revenue of $346 million, up 5% on a reported basis and 9% organically excluding CSL, as strength in its Plasma and Blood Management Technologies businesses offset continued pressure in Interventional Technologies. President and CEO Christopher S
Haemonetics (HAE) Q4 2026 Earnings Transcript
Olga Guyette: Good morning, and thank you for joining us for Haemonetics' Fourth Quarter Fiscal Year 2026 Conference Call and Webcast. This morning, we released our fourth quarter and full fiscal 2026 results and issued fiscal year 2027 guidance. The materials, including our earnings release and supplemental earnings presentation, are available on our Investor Relations website and also in this morning's press release.
Haemonetics Corporation Q4 2026 Earnings Call Summary
Moby summary of Haemonetics Corporation's Q4 2026 earnings call
Haemonetics (HAE) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Haemonetics (HAE) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.